Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% ...

Biogen Inc. (NASDAQ:BIIB), currently valued at $19.15 billion by market capitalization, reported its earnings for the fourth quarter of 2024, surpassing analysts' expectations with a non-GAAP diluted ...

Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to ...

Wednesday closed down -0.27%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.50%, and the Nasdaq 100 Index ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB ...

The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly three months after it recommended approval for the drug to treat some patients ...

The decision means that Vumerity (diroximel fumarate) – a follow-up to Biogen's older oral therapy Tecfidera (dimethyl fumarate) – is now available to eligible patients across the UK ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

Eisai and Biogen have moved swiftly ahead with regulatory ... although it is reviewing its policy on amyloid-targeting drugs. In the UK – where use of the drug in England, Scotland, and Wales ...